As a result of Concord’s investment, MindMaze will initiate a partnership with The American Hospital Association
The Hinduja supported MindMaze has announced that it has secured a $105 million financing round to accelerate its global commercial growth plans, supercharge ongoing R&D and consolidate the clinical development pipeline of its industry- defining digital therapeutic solutions for a wide spectrum of neurological diseases.
The financing round provides immediate access to funds, and a financing facility to fund growth and future acquisitions. The financing was led by Concord Health Partners, a US-based healthcare private equity firm focused on investing in and supporting healthcare companies with innovative technologies and solutions that address quality, cost and access to care along with other investors. AlbaCore Capital Group are building on their existing investment. This round also included participation from London-based Hambro Perks.
Furthermore, as a result of Concord’s investment, MindMaze will initiate a partnership with The American Hospital Association (“AHA”). The AHA works towards advancement of innovative healthcare solutions, including nearly 90 per cent of US hospitals, health systems and other health care organisations as well as 300,000 executives from health care organizations in the field.
Hinduja supported MindMaze is ISO 13485 certified and its product portfolio has received three FDA clearances and four CE marks across multiple clinical indications. With this financing in place, the company also plans to invest in partnerships with pharmaceutical and medical device companies; expand on work with top academic institutions. With over 10 clinical trials underway across 8 indications, the company expects to have at least three new prescription digital therapeutic solutions for chronic stroke, Parkinson’s Disease, and aging/MCI in the next few years.